abstract |
The present invention describes a method of therapeutically treating a mammal, including but not limited to human, to increase the relative insulin producing capacity of endogenous pancreatic β-cells and to differentiate pancreatic epithelial cells into insulin producing β-cells. Oral administration of DP IV inhibitors preserves the active form of GLP-1 for longer periods of time under physiological conditions. In particular, the prolonged presence of GLP-1 in pancreatic tissue promotes the differentiation and regeneration of existing β-cells in need of healing. The cured insulin producing cells may contribute to the correction and maintenance of normal physiological blood glucose levels. |